Want to see SKYE full AI Analyst Report?
SKYE Stock Chart & Stats
$0.79
-$0.06(-1.95%)
At close: 4:00 PM EST
$0.79
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$0.57 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)182.32K
Market Cap
$24.62M
Enterprise Value$17.17M
Total Cash (Recent Filing)$17.11M
Total Debt (Recent Filing)$311.32K
Price to Earnings (P/E)―
Beta3.20
Next Earnings
Aug 07, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding35,143,723
10 Day Avg. Volume173,215
30 Day Avg. Volume182,318
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-99.30
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$13.00Price Target Upside1545.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company’s minimal debt and ~0.01 debt-to-equity materially reduce interest and refinancing pressure, preserving financing optionality. Over 2–6 months this lowers bankruptcy risk and gives management time to pursue financing or partnerships without heavy fixed-charge constraints.
Clinical-stage Cannabinoid FocusSkye’s focus on cannabinoid-based therapeutics targeting the endocannabinoid system and CB1 for metabolic disease establishes a differentiated R&D niche. If clinical progress continues, this structural specialization could create durable IP-driven competitive advantages and address large unmet markets.
Capital-raising Flexibility & Governance SupportExpanding authorized shares plus shareholder re-approval of directors and auditor gives management formal flexibility to raise capital, execute strategic transactions, or issue equity for partnerships. Combined with shareholder backing, this supports longer-term funding options if needed.
Bears Say
No Revenue; Heavy Cash BurnSustained zero revenue with large TTM losses and roughly -$42M free cash flow implies continued reliance on external financing. Over months this depletes liquidity, constrains R&D runway absent fundraising, and increases execution risk if capital markets tighten or dilution becomes necessary.
Eroding Equity BaseA sharp decline in stockholders’ equity signals sustained losses and capital consumption, weakening the balance sheet. Over 2–6 months this limits strategic flexibility, heightens the probability of dilutive financings, and undermines resilience to unexpected shocks or extended clinical timelines.
Nasdaq Listing & Compliance RiskTransfer to the lower-tier Nasdaq Capital Market and an outstanding minimum bid-price deficiency create structural listing risk and potential governance distractions. If unresolved, these issues can reduce investor access, increase fundraising costs, and limit strategic transactions over the medium term.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.56 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $24.62M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 33 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on May 11, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.309 by -$0.011.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 35,143,723 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.309. Following the earnings report the stock price went down -7.614%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
SKYE Company Deck
SKYE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$13.00
▲(1545.57% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
57.51% Insiders
2.73% Mutual Funds
6.38% Other Institutional Investors
31.12% Public Companies and
Individual Investors